Diabetes Canada2018EN
Diabetes Canada Chapter 30: Retinopathy
Zusammenfassung
KEY MESSAGES:
Key Messages Regular screening is important for early detection of treatable diabetic retinopathy. Screening intervals for diabetic retinopathy vary according to the individuals age and type of diabetes. Optimal glycemic control reduces the onset and progression of sight-threatening diabetic retinopathy. Local intraocular pharmacological therapies have the potential to improve vision and reduce the level of retinopathy. Key Messages for People with Diabetes Diabetic retinopathy inv
Kerninformationen
in Indigenous populations in Canada (4,5) . Visual loss is associated with significant morbidity, including increased falls, hip fracture and a 4-fold increase in mortality (6) . Among individuals with type 1 diabetes, limb amputation and visual loss due to diabetic retinopathy are independent predi...
exudates (9) . Use of OCT technology more accurately measures and quantifies retinal thickening threatening the foveal centre; this imaging modality has encouraged the terminology "centre-involving" DME to guide therapeutic decisions. Since therapies are available for sight-threatening diabetic reti...
edema (16,20,21) . Screening frequency for retinopathy has been extensively evaluated through post-hoc statistical modelling of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC), and results suggest that frequency can be individua...
Fragen zu diesem Thema?
ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.
Jetzt auf ClariMed suchenVerwandte Leitlinien
Cochrane2023
Cochrane Review: Blood pressure control for diabetic retinopathy
Cochrane2020
Cochrane Review: Intravitreal steroids for macular edema in diabetes
AWMF2025
AWMF 045-024: Spezielle Diagnostik und Therapie von Netzhautkomplikationen bei Diabetes
SIGN2017
SIGN 116: Management of Diabetes
Cochrane2023
Cochrane Review: Fenofibrate for diabetic retinopathy
DDG2025
DDG: 045-024l_S3_Spezielle-Diagnostik-Therapie-Netzhautkomplikationen-Diabetes_2025-08.pdf pdf
SIGN2010